Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS)
Clara Health

Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS)

Sponsored by Intermountain Health Care


This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating hospitalized patients with suspected or confirmed COVID-19.

About 
COVID-19

Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.

How is this study designed?

Study Type: Interventional (Clinical Trial) Estimated Enrollment: 300 participants Primary Purpose: Treatment Actual Study Start Date: March 30, 2020 Estimated Study Completion Date: December 31, 2021

Who is this study for?

Inclusion Criteria*:

  • Adult (age ≥ 18 years)
  • Confirmed OR suspected COVID-19,
    • Confirmed: Positive assay for COVID-19 within the last 10 days
    • Suspected: Pending assay for COVID-19 WITH high clinical suspicion
  • Scheduled for admission or already admitted to an inpatient bed
  • Patients must be enrolled within 48 hours of hospital admission

Exclusion Criteria*:

  • Pregnant or nursing
  • Weight < 35kg

* Additional criteria apply. Please speak with the study team for further information.

What should I expect?

Arm 1: Hydroxychloroquine Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate)<50ml/min).

Arm 2: Azithromycin Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization, the prior doses will count toward the 5-day total.

Inpatient trial

Have questions or need help?

For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.